Literature DB >> 24385344

Fatty acid nitroalkenes ameliorate glucose intolerance and pulmonary hypertension in high-fat diet-induced obesity.

Eric E Kelley1, Jeff Baust, Gustavo Bonacci, Franca Golin-Bisello, Jason E Devlin, Claudette M St Croix, Simon C Watkins, Sonia Gor, Nadiezhda Cantu-Medellin, Eric R Weidert, Jefferson C Frisbee, Mark T Gladwin, Hunter C Champion, Bruce A Freeman, Nicholas K H Khoo.   

Abstract

AIMS: Obesity is a risk factor for diabetes and cardiovascular diseases, with the incidence of these disorders becoming epidemic. Pathogenic responses to obesity have been ascribed to adipose tissue (AT) dysfunction that promotes bioactive mediator secretion from visceral AT and the initiation of pro-inflammatory events that induce oxidative stress and tissue dysfunction. Current understanding supports that suppressing pro-inflammatory and oxidative events promotes improved metabolic and cardiovascular function. In this regard, electrophilic nitro-fatty acids display pleiotropic anti-inflammatory signalling actions. METHODS AND
RESULTS: It was hypothesized that high-fat diet (HFD)-induced inflammatory and metabolic responses, manifested by loss of glucose tolerance and vascular dysfunction, would be attenuated by systemic administration of nitrooctadecenoic acid (OA-NO2). Male C57BL/6j mice subjected to a HFD for 20 weeks displayed increased adiposity, fasting glucose, and insulin levels, which led to glucose intolerance and pulmonary hypertension, characterized by increased right ventricular (RV) end-systolic pressure (RVESP) and pulmonary vascular resistance (PVR). This was associated with increased lung xanthine oxidoreductase (XO) activity, macrophage infiltration, and enhanced expression of pro-inflammatory cytokines. Left ventricular (LV) end-diastolic pressure remained unaltered, indicating that the HFD produces pulmonary vascular remodelling, rather than LV dysfunction and pulmonary venous hypertension. Administration of OA-NO2 for the final 6.5 weeks of HFD improved glucose tolerance and significantly attenuated HFD-induced RVESP, PVR, RV hypertrophy, lung XO activity, oxidative stress, and pro-inflammatory pulmonary cytokine levels.
CONCLUSIONS: These observations support that the pleiotropic signalling actions of electrophilic fatty acids represent a therapeutic strategy for limiting the complex pathogenic responses instigated by obesity.

Entities:  

Keywords:  Inflammation; Nitro-fatty acid signalling; Obesity; Pulmonary hypertension; Xanthine Oxidase

Mesh:

Substances:

Year:  2014        PMID: 24385344      PMCID: PMC3928004          DOI: 10.1093/cvr/cvt341

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  42 in total

1.  Modulation of in vivo cardiac function by myocyte-specific nitric oxide synthase-3.

Authors:  Hunter C Champion; Dimitrios Georgakopoulos; Eiki Takimoto; Takayoshi Isoda; Yibin Wang; David A Kass
Journal:  Circ Res       Date:  2004-01-29       Impact factor: 17.367

2.  Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the Registry to Evaluate Early and Long-term PAH Disease Management with normative values from the National Health and Nutrition Examination Survey.

Authors:  Charles D Burger; Aimee J Foreman; Dave P Miller; Robert E Safford; Michael D McGoon; David B Badesch
Journal:  Mayo Clin Proc       Date:  2011-02       Impact factor: 7.616

Review 3.  Nitro-fatty acid formation and signaling.

Authors:  Bruce A Freeman; Paul R S Baker; Francisco J Schopfer; Steven R Woodcock; Alessandra Napolitano; Marco d'Ischia
Journal:  J Biol Chem       Date:  2008-02-19       Impact factor: 5.157

4.  Upregulation of xanthine oxidase by lipopolysaccharide, interleukin-1, and hypoxia. Role in acute lung injury.

Authors:  P M Hassoun; F S Yu; C G Cote; J J Zulueta; R Sawhney; K A Skinner; H B Skinner; D A Parks; J J Lanzillo
Journal:  Am J Respir Crit Care Med       Date:  1998-07       Impact factor: 21.405

5.  Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production.

Authors:  Umair Z Malik; Nicholas J Hundley; Guillermo Romero; Rafael Radi; Bruce A Freeman; Margaret M Tarpey; Eric E Kelley
Journal:  Free Radic Biol Med       Date:  2011-04-15       Impact factor: 7.376

Review 6.  Adipokines in inflammation and metabolic disease.

Authors:  Noriyuki Ouchi; Jennifer L Parker; Jesse J Lugus; Kenneth Walsh
Journal:  Nat Rev Immunol       Date:  2011-01-21       Impact factor: 53.106

7.  Protein carbonyl groups as biomarkers of oxidative stress.

Authors:  Isabella Dalle-Donne; Ranieri Rossi; Daniela Giustarini; Aldo Milzani; Roberto Colombo
Journal:  Clin Chim Acta       Date:  2003-03       Impact factor: 3.786

8.  Pulmonary and cardiovascular complications of obesity: an autopsy study of 76 obese subjects.

Authors:  Abida K Haque; Swarupa Gadre; Jerrod Taylor; Sajid A Haque; Daniel Freeman; Alex Duarte
Journal:  Arch Pathol Lab Med       Date:  2008-09       Impact factor: 5.534

9.  Nitrolinoleate inhibits superoxide generation, degranulation, and integrin expression by human neutrophils: novel antiinflammatory properties of nitric oxide-derived reactive species in vascular cells.

Authors:  Barbara Coles; Allison Bloodsworth; Stephen R Clark; Malcolm J Lewis; Andrew R Cross; Bruce A Freeman; Valerie B O'Donnell
Journal:  Circ Res       Date:  2002-09-06       Impact factor: 17.367

10.  Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension.

Authors:  Alice Huertas; Ly Tu; Natalia Gambaryan; Barbara Girerd; Frédéric Perros; David Montani; Dominique Fabre; Elie Fadel; Saadia Eddahibi; Sylvia Cohen-Kaminsky; Christophe Guignabert; Marc Humbert
Journal:  Eur Respir J       Date:  2012-02-23       Impact factor: 16.671

View more
  44 in total

1.  Mouse Genome-Wide Association Study of Preclinical Group II Pulmonary Hypertension Identifies Epidermal Growth Factor Receptor.

Authors:  Neil J Kelly; Josiah E Radder; Jeffrey J Baust; Christine L Burton; Yen-Chun Lai; Karin C Potoka; Brittani A Agostini; John P Wood; Timothy N Bachman; Rebecca R Vanderpool; Nadine Dandachi; Adriana S Leme; Alyssa D Gregory; Alison Morris; Ana L Mora; Mark T Gladwin; Steven D Shapiro
Journal:  Am J Respir Cell Mol Biol       Date:  2017-04       Impact factor: 6.914

2.  Conjugated Linoleic Acid Modulates Clinical Responses to Oral Nitrite and Nitrate.

Authors:  Kara S Hughan; Stacy Gelhaus Wendell; Meghan Delmastro-Greenwood; Nicole Helbling; Catherine Corey; Landon Bellavia; Gopal Potti; George Grimes; Bret Goodpaster; Daniel B Kim-Shapiro; Sruti Shiva; Bruce A Freeman; Mark T Gladwin
Journal:  Hypertension       Date:  2017-09       Impact factor: 10.190

Review 3.  Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health.

Authors:  Carl D Koch; Mark T Gladwin; Bruce A Freeman; Jon O Lundberg; Eddie Weitzberg; Alison Morris
Journal:  Free Radic Biol Med       Date:  2016-12-16       Impact factor: 7.376

4.  Generation and esterification of electrophilic fatty acid nitroalkenes in triacylglycerides.

Authors:  Marco Fazzari; Nicholas Khoo; Steven R Woodcock; Lihua Li; Bruce A Freeman; Francisco J Schopfer
Journal:  Free Radic Biol Med       Date:  2015-06-09       Impact factor: 7.376

5.  The Chemical Basis of Thiol Addition to Nitro-conjugated Linoleic Acid, a Protective Cell-signaling Lipid.

Authors:  Lucía Turell; Darío A Vitturi; E Laura Coitiño; Lourdes Lebrato; Matías N Möller; Camila Sagasti; Sonia R Salvatore; Steven R Woodcock; Beatriz Alvarez; Francisco J Schopfer
Journal:  J Biol Chem       Date:  2016-12-06       Impact factor: 5.157

6.  Nitro-oleic acid and epoxyoleic acid are not altered in obesity and type 2 diabetes: reply.

Authors:  Francisco J Schopfer; Bruce A Freeman; Nicholas K H Khoo
Journal:  Cardiovasc Res       Date:  2014-02-21       Impact factor: 10.787

Review 7.  Nitro-fatty acids: New drug candidates for chronic inflammatory and fibrotic diseases.

Authors:  Francisco J Schopfer; Dario A Vitturi; Diane K Jorkasky; Bruce A Freeman
Journal:  Nitric Oxide       Date:  2018-06-23       Impact factor: 4.427

Review 8.  Models and Molecular Mechanisms of World Health Organization Group 2 to 4 Pulmonary Hypertension.

Authors:  Ping Yu Xiong; Francois Potus; Winnie Chan; Stephen L Archer
Journal:  Hypertension       Date:  2017-11-20       Impact factor: 10.190

Review 9.  Inflammatory signaling and metabolic regulation by nitro-fatty acids.

Authors:  Oren Rom; Nicholas K H Khoo; Y Eugene Chen; Luis Villacorta
Journal:  Nitric Oxide       Date:  2018-03-22       Impact factor: 4.427

10.  Nitrite and nitrate-dependent generation of anti-inflammatory fatty acid nitroalkenes.

Authors:  Meghan Delmastro-Greenwood; Kara S Hughan; Dario A Vitturi; Sonia R Salvatore; George Grimes; Gopal Potti; Sruti Shiva; Francisco J Schopfer; Mark T Gladwin; Bruce A Freeman; Stacy Gelhaus Wendell
Journal:  Free Radic Biol Med       Date:  2015-09-16       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.